Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 12, 2026, titled "Zydus expands companion diagnostics portfolio with the launch of AI-powered Continuous Glucose Monitor DiasensTM and GlucoLiveTM".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has launched two new AI-powered Continuous Glucose Monitors (CGMs) — Diasens™ and GlucoLive™ — as part of its companion diagnostics portfolio. The devices are aimed at diabetic, Chronic Kidney Disease (CKD), and post-transplant patients, and automatically stream glucose readings to a smartphone every 3 minutes without manual scanning, unlike most existing Indian CGM devices that rely on NFC. The CGMs are integrated with TatvaCare's GoodFlip™ app, offering AI-driven analytics, personalised diet and exercise coaching, doctor consultations, and a clinician remote-monitoring dashboard. India has over 101 million diabetic adults and 136 million pre-diabetics, making this a large addressable market, and the launch strengthens Zydus's move into digital health and chronic disease management.
This launch diversifies Zydus's revenue stream beyond its core pharma business into the fast-growing digital diagnostics and consumer health segment, with potential to capture share in India's massive diabetic population. Near-term stock impact may be limited as revenue contribution depends on adoption and pricing, but it strengthens Zydus's innovation-led growth narrative.